---
title: "Hemogenyx Raises £2.5m to Advance CAR-T Trials in Adult and Pediatric AML"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275486211.md"
description: "HemoGenyx Pharmaceuticals has raised £2.5 million from private investors through a direct subscription for new shares, funding its Phase I clinical trials for HG-CT-1, a CAR-T therapy for acute myeloid leukemia. The company has received FDA clearance for a pediatric trial and aims to reduce costs by outsourcing manufacturing. Despite ongoing losses and cash burn, analysts rate the stock as a Hold with a price target of £725.00, while Spark's AI Analyst gives it a Neutral score due to weak financial performance and high balance-sheet risk."
datetime: "2026-02-10T15:57:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275486211.md)
  - [en](https://longbridge.com/en/news/275486211.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275486211.md)
---

# Hemogenyx Raises £2.5m to Advance CAR-T Trials in Adult and Pediatric AML

### Valentine's Day Sale - 70% Off

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has provided an announcement.

Hemogenyx Pharmaceuticals has raised £2.5 million from a consortium of private investors via a direct subscription for 333,333 new shares at £7.50 each, alongside three-year warrants exercisable at £9, increasing its issued share capital to 6,374,588 shares. The funding will primarily support the continuation and dose escalation of its Phase I clinical trials for HG-CT-1, a CAR-T therapy for relapsed or refractory acute myeloid leukemia in adults and newly cleared pediatric patients, while the company also cuts costs by outsourcing manufacturing to Made Scientific and continues to advance its CDX and CBR programmes.

The company has received a positive recommendation from the independent Data Safety Monitoring Board to proceed to the next dose level in adults and secured U.S. FDA clearance to begin a pediatric Phase I trial for patients aged 12–18, positioning HG-CT-1 as its lead value driver. Management has focused on reducing burn rate through operational efficiencies, including the external manufacturing transfer, and maintains that progress on its broader pipeline will be reported in due course, with the new capital and admission of the placing shares expected to reinforce its financial footing and market presence.

The most recent analyst rating on (GB:HEMO) stock is a Hold with a £725.00 price target. To see the full list of analyst forecasts on HemoGenyx Pharmaceuticals Plc stock, see the GB:HEMO Stock Forecast page.

**Spark’s Take on GB:HEMO Stock**

According to Spark, TipRanks’ AI Analyst, GB:HEMO is a Neutral.

The score is held down primarily by very weak financial performance (no revenue, ongoing losses and cash burn, and higher balance-sheet risk from lower equity and increased leverage). Technicals provide some offset with strong recent momentum, but overbought indicators add near-term risk, and valuation support is limited due to a negative P/E and no dividend yield.

To see Spark’s full report on GB:HEMO stock, click here.

**More about HemoGenyx Pharmaceuticals Plc**

Hemogenyx Pharmaceuticals plc is a clinical-stage biopharmaceutical company listed on the London Stock Exchange and headquartered in London, with operating subsidiaries in New York City. The company develops novel medicines and treatments for blood and autoimmune diseases, built around several complementary product candidates and platform technologies for innovative drug development.

**Average Trading Volume:** 44,007

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** £66.45M

For a thorough assessment of HEMO stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [HEPA.US](https://longbridge.com/en/quote/HEPA.US.md)
- [426CVR015TMP.US](https://longbridge.com/en/quote/426CVR015TMP.US.md)

## Related News & Research

- [Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results | PFE Stock News](https://longbridge.com/en/news/287035698.md)
- [Project helps turn around lives of special needs children and their parents](https://longbridge.com/en/news/286424988.md)
- [BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency | BMRN Stock News](https://longbridge.com/en/news/286776398.md)
- [05:20 ETThrough the America's Most Artistic Kid Competition, Colossal Raises $1.6 Million While Celebrating the Next Gen of Creative Visionaries](https://longbridge.com/en/news/287037755.md)
- [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md)